Compare GSK Pharma with ALEMBIC LTD - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GSK PHARMA vs ALEMBIC LTD - Comparison Results

GSK PHARMA     Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

ALEMBIC LTD 
   Change

Alembic Limited, in its 99 years of existence, has evolved from being a tincture manufacturer to one of the prominent indigenous pharma companies in India. It is among the top players in the macrolides (anti-infective) and anti-microbials (animal hea... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GSK PHARMA ALEMBIC LTD GSK PHARMA/
ALEMBIC LTD
 
P/E (TTM) x 32.3 74.4 43.4% View Chart
P/BV x 12.9 2.6 487.0% View Chart
Dividend Yield % 1.2 0.4 318.7%  

Financials

 GSK PHARMA   ALEMBIC LTD
EQUITY SHARE DATA
    GSK PHARMA
Mar-19
ALEMBIC LTD
Mar-18
GSK PHARMA/
ALEMBIC LTD
5-Yr Chart
Click to enlarge
High Rs3,59572 4,993.1%   
Low Rs1,25334 3,696.2%   
Sales per share (Unadj.) Rs184.74.7 3,928.4%  
Earnings per share (Unadj.) Rs26.36.1 430.8%  
Cash flow per share (Unadj.) Rs29.26.2 466.9%  
Dividends per share (Unadj.) Rs20.000.20 10,000.0%  
Dividend yield (eoy) %0.80.4 218.4%  
Book value per share (Unadj.) Rs126.340.7 310.7%  
Shares outstanding (eoy) m169.40267.03 63.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x13.111.3 116.5%   
Avg P/E ratio x92.28.7 1,062.7%  
P/CF ratio (eoy) x83.18.5 980.4%  
Price / Book Value ratio x19.21.3 1,473.6%  
Dividend payout %76.13.3 2,321.4%   
Avg Mkt Cap Rs m410,62614,139 2,904.2%   
No. of employees `0005.0NA-   
Total wages/salary Rs m5,372207 2,590.2%   
Avg. sales/employee Rs Th6,306.7NM-  
Avg. wages/employee Rs Th1,083.1NM-  
Avg. net profit/employee Rs Th898.0NM-  
INCOME DATA
Net Sales Rs m31,2811,255 2,492.1%  
Other income Rs m1,023370 276.4%   
Total revenues Rs m32,3041,625 1,987.5%   
Gross profit Rs m6,009111 5,408.5%  
Depreciation Rs m48638 1,285.7%   
Interest Rs m62 352.9%   
Profit before tax Rs m6,540442 1,480.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m01,212 0.0%   
Extraordinary Inc (Exp) Rs m2870-   
Tax Rs m2,37324 9,908.1%   
Profit after tax Rs m4,4541,630 273.3%  
Gross profit margin %19.28.9 217.0%  
Effective tax rate %36.35.4 669.3%   
Net profit margin %14.2129.8 11.0%  
BALANCE SHEET DATA
Current assets Rs m20,0611,867 1,074.5%   
Current liabilities Rs m14,543591 2,459.9%   
Net working cap to sales %17.6101.6 17.4%  
Current ratio x1.43.2 43.7%  
Inventory Days Days5794 60.2%  
Debtors Days Days1474 19.1%  
Net fixed assets Rs m14,3431,791 800.9%   
Share capital Rs m1,694534 317.2%   
"Free" reserves Rs m19,70410,324 190.9%   
Net worth Rs m21,39810,858 197.1%   
Long term debt Rs m241 4.9%   
Total assets Rs m39,11311,591 337.5%  
Interest coverage x1,091.0260.9 418.2%   
Debt to equity ratio x00 2.5%  
Sales to assets ratio x0.80.1 738.5%   
Return on assets %11.414.1 81.0%  
Return on equity %20.815.0 138.7%  
Return on capital %31.915.2 210.2%  
Exports to sales %01.5 0.0%   
Imports to sales %021.0 0.0%   
Exports (fob) Rs mNA19 0.0%   
Imports (cif) Rs mNA263 0.0%   
Fx inflow Rs m53419 2,752.6%   
Fx outflow Rs m7,091264 2,687.8%   
Net fx Rs m-6,557-244 2,682.7%   
CASH FLOW
From Operations Rs m3,994236 1,693.7%  
From Investments Rs m-1,433-224 639.9%  
From Financial Activity Rs m-3,584-27 13,472.2%  
Net Cashflow Rs m-1,023-15 6,913.5%  

Share Holding

Indian Promoters % 0.0 64.0 -  
Foreign collaborators % 50.7 0.0 -  
Indian inst/Mut Fund % 10.2 0.2 5,100.0%  
FIIs % 23.8 9.7 245.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 15.4 26.1 59.0%  
Shareholders   102,036 54,701 186.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GSK PHARMA With:   IPCA LABS  SANOFI INDIA  DR. DATSONS LABS  PROCTER & GAMBLE HEALTH  NOVARTIS  

Compare GSK PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 72 Points Lower; Capital Goods and Auto Stocks Witness Selling(Closing)

India share markets witnessed selling pressure during closing hours and ended their day marginally lower.

Related Views on News

GSK PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 398.9% (Quarterly Result Update)

Oct 25, 2019 | Updated on Oct 25, 2019

For the quarter ended September 2019, GSK PHARMA has posted a net profit of Rs 5 bn (up 398.9% YoY). Sales on the other hand came in at Rs 9 bn (up 8.1% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

ALEMBIC LTD Announces Quarterly Results (1QFY20); Net Profit Down 70.9% (Quarterly Result Update)

Aug 27, 2019 | Updated on Aug 27, 2019

For the quarter ended June 2019, ALEMBIC LTD has posted a net profit of Rs 20 m (down 70.9% YoY). Sales on the other hand came in at Rs 260 m (down 41.5% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

GSK PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 28.1% (Quarterly Result Update)

Jul 24, 2019 | Updated on Jul 24, 2019

For the quarter ended June 2019, GSK PHARMA has posted a net profit of Rs 1 bn (up 28.1% YoY). Sales on the other hand came in at Rs 8 bn (up 7.1% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

GSK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 24, 2019 | Updated on Jun 24, 2019

Here's an analysis of the annual report of GSK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GSK PHARMA. Also includes updates on the valuation of GSK PHARMA.

GSK PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 16.6% (Quarterly Result Update)

May 21, 2019 | Updated on May 21, 2019

For the quarter ended March 2019, GSK PHARMA has posted a net profit of Rs 1 bn (up 16.6% YoY). Sales on the other hand came in at Rs 8 bn (up 0.3% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

More Views on News

Most Popular

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

Why Moody's Rating Downgrade is a Strong Sign to Buy Stocks(The 5 Minute Wrapup)

Nov 8, 2019

Investors who took cues from Moody's rating downgrade in 1992 and 2002 created some of the biggest wealth of their lifetime.

These 10 Days Are Crucial for Getting Rich in the Smallcap Rebound(Profit Hunter)

Nov 5, 2019

How to avoid the most common investing mistake and make the most of the smallcap rebound.

The Top Stocks for 2020 Pass This Most Critical Metric(The 5 Minute Wrapup)

Nov 5, 2019

Charlie Munger's favorite fictional character, Mr Glotz, picks stocks using this metric.

A Trade that Could Generate Profits for Decades

Nov 14, 2019

India's #1 trader is back on the Investor Hour. Vijay Bhambwani talks to us about his super-profitable trading system and shares with us his #1 long term trade. Listen in...

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

GSK PHARMA SHARE PRICE


Nov 18, 2019 (Close)

TRACK GSK PHARMA

  • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

GSK PHARMA - AUROBINDO PHARMA COMPARISON

COMPARE GSK PHARMA WITH

MARKET STATS